LYON, France, Nov. 8, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces, together with their South African distributors, Intamed, the launch of Ablatherm-HIFU services located at The Christiaan Barnard Memorial Hospital, Cape Town, South Africa. The first treatment sessions were performed in October by Dr. Stephen Eppel with renowned Ablatherm user Dr. Stefan Thuroff from Klinikum Harlaching, Munich, assisting as mentor. Ablatherm will be available to South African patients as well as to patients from all countries in Africa.

Intamed placed the unit at Christiaan Barnard Memorial (CBM) Hospital, part of The Netcare Group, the largest private Hospital Group in South Africa. CBM is backed by state-of-the-art technology providing a wide range of specialist services. Intamed together with Dr. Stephen Eppel recently decided to offer Ablatherm-HIFU to South African patients after extensive review of the clinical documentation discussing its benefits and outcomes for localized prostate cancer.

Dr. Stephen Eppel studied medicine in South Africa specializing in Urology. He then moved to the United States where he spent time practicing Academic Urology at The Universities of Tennessee and Minnesota for 7 years, including a two-year Professorship. He was awarded a fellowship at Baylor College of Medicine. This was followed by a further 13 years in a successful private practice in Memphis, Tennessee where he and his group treated prostate cancer patients using the standard treatment alternatives: Radical Prostatectomy including Robotic, Radio-active Seed Implantation (Brachytherapy), External Beam Radiation including IMRT, and Cryosurgery. While practicing in the U.S., he had the opportunity to use both Ablatherm and competing HIFU technology in Mexico and Canada. He returned to South Africa with his family in 2006 to start a private practice based at the CBM Hospital. Dr. Eppel has now elected to be the first South African Urologist to offer Ablatherm-HIFU treatments.

Dr. Eppel commented, "I was strongly impressed by the safety features integral to the Ablatherm device as compared to other technology. These precautions combined with the strong documented clinical outcomes are attractive to doctors seeking alternatives for patients with prostate cancer. Having examined and used both HIFU technologies, the extensive training, documentation and local support provided by Intamed and EDAP made me decide in favor of the Ablatherm. I was also able to study its use at several European locations alongside global HIFU experts committed to the Ablatherm technology."

INTAMED, part of Intamarket Group, has specialized in the distribution of high technology products for more than 35 years. They distribute capital medical equipment on behalf of significant international brands to the healthcare industries in South Africa and neighboring countries.

Gary Wachsberger, Director of Intamed, commented, "We are very excited to include Ablatherm-HIFU in our portfolio, especially launching this important service for South African patients. With the marketplace moving toward less invasive technology with greater patient consideration, Ablatherm combines safety, efficacy and patient care into a compelling package for any urological practice."

Marc Oczachowski, CEO of EDAP, stated, "We are pleased to open a new regional market for Ablatherm-HIFU, especially with a user who has experience in multiple HIFU options and chose Ablatherm as the top technology for its safety and outcomes. Once again the innovative RPP program EDAP pioneered allows this treatment option to enter new markets and benefit patients by making Ablatherm financially accessible to hospitals. Ablatherm is now very active and routinely used in more than twenty countries. EDAP's aggressive education programs implemented in key European countries are opening opportunities in new global markets as an added benefit to the strong growth results in their original territories."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is a treatment for patients with newly diagnosed localized prostate cancer or who have failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

To sign up for alerts please visit: http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT:  EDAP TMS S.A.
          Blandine Confort
          +33 4 78 26 40 46

          Magnolia Investor Relations 
          Matt Kreps
          469 362-5960